Trial: 201908073

Randomized, double-blind, phase 3 of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer

Phase

III

Principal Investigator

Frith, Ashley

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov